Caverject
Caverject Brand names, Caverject Analogs
Caverject Brand Names Mixture
- No information avaliable
Caverject Chemical_Formula
C20H34O5
Caverject RX_link
http://www.rxlist.com/cgi/generic/alprostadil.htm
Caverject fda sheet
Caverject msds (material safety sheet)
Caverject Synthesis Reference
No information avaliable
Caverject Molecular Weight
354.481 g/mol
Caverject Melting Point
115 - 116 oC
Caverject H2O Solubility
26.7 mg/L
Caverject State
Solid
Caverject LogP
2.983
Caverject Dosage Forms
Liquid; Powder for solution; Solution; Suppository
Caverject Indication
For palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Also for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.
Caverject Pharmacology
Alprostadil (prostaglandin E1) is produced endogenously to relax vascular smooth muscle and cause vasodilation. In adult males, the vasodilatory effects of alprostadil on the cavernosal arteries and the trabecular smooth muscle of the corpora cavernosa result in rapid arteriolar inflow and expansion of the lacunar spaces within the corpora. As the expanded corporal sinusoids are compressed against the tunica albuginea, venous outflow through the subtunical vessels is impeded and penile rigidity develops. This is referred to as the corporal veno-occlusive mechanism. In infants, the vasodilatory effects of alprostadil increase pulmonary or systemic blood flow.
Caverject Absorption
The absolute bioavailability of alprostadil has not been determined.
Caverject side effects and Toxicity
Oral, mouse: LD50 = 186 mg/kg; Oral, rat: LD50 = 228 mg/kg. Apnea, bradycardia, pyrexia, hypotension, and flushing may be signs of drug overdosage.
Caverject Patient Information
Caverject Organisms Affected
Humans and other mammals
